Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Alastair Greystoke.

Newcastle AuthorsTitleYearFull text
Jakub Chmelo
Alexander Phillips
Dr Alastair Greystoke
Dr Sarah Charman
Dr Leah Avery
et al.
A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme: the ChemoFit study2022
Jakub Chmelo
Dr Rhona Sinclair
Dr Sarah Charman
Dr Kate Hallsworth
Jenny Welford
et al.
Exploring factors influencing uptake and adherence to a home-based prehabilitation physical activity and exercise intervention for patients undergoing chemotherapy before major surgery (ChemoFit): a qualitative study2022
Dr Alastair Greystoke
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study2022
Jakub Chmelo
Alexander Phillips
Dr Alastair Greystoke
Dr Alex Bradshaw
Dr Rhona Sinclair
et al.
Comparison of the effects of FLOT and ECX chemotherapy for oesophagogastric adenocarcinoma on cardiopulmonary reserve2021
Dr Alastair Greystoke
Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer2021
Jakub Chmelo
Alexander Phillips
Dr Alastair Greystoke
Dr Sarah Charman
Dr Leah Avery
et al.
A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol2020
Ruth Norris
Dr Rosie Dew
Professor Linda Sharp
Dr Alastair Greystoke
Dr Sarah Rice
et al.
Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis2020
Dr Nicola Hannaway
Dr Alastair Greystoke
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer2020
Dr Eleanor Smith
Dr Alastair Greystoke
The care of older cancer patients in the United Kingdom2020
Dr Alastair Greystoke
The National Lung Matrix Trial of personalised therapy in lung cancer2020
Dr Alastair Greystoke
105O - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study2019
Dr Alastair Greystoke
140P - Brigatinib experience on the ALK project2019
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019
Alice Coomer
Dr Fiona Black
Dr Alastair Greystoke
Dr Jennifer Munkley
Professor David Elliott
et al.
Alternative splicing in lung cancer2019
Dr Alastair Greystoke
Implications for UK practice of the use of durvalumab in stage III NSCLC2019
Dr Alastair Greystoke
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomalformulation in patients with solid tumours2019
Dr Maziar Navidi
Alexander Phillips
Professor Michael Griffin
Dr Alastair Greystoke
Dr Kate Sumpter
et al.
Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer2018
Dr Joanna Perthen
Dr Tamir Ali
David McCulloch
Maziar Navidi
Alexander Phillips
et al.
Intra- and Interobserver Variability in Skeletal Muscle Measurements using Computed Tomography Images2018
Dr Alastair Greystoke
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)2017
Dr Alastair Greystoke
Dr Noor MD Haris
Professor Ruth Plummer
SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Nicola Wyatt
Dr Linda Hogarth
Dianne Turner
Dr Miranda Patterson
Dr David Jamieson
et al.
Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)2016
Dr Sally Hall
Dr Alastair Greystoke
Dr Christopher Jones
Dr Jane Margetts
Crizotinib in clinical practice: the North East of England's experience2016
Dr Alastair Greystoke
Development of a circulating miRNA assay to monitor tumor burden: From mouse to man2016
Professor Ruth Plummer
Dr Alastair Greystoke
SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting2016
Dr Alastair Greystoke
Dr Linda Hogarth
Dr Miranda Morton
Liam Bolt
Dianne Turner
et al.
The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained2016
Dr Yvette Drew
Dr Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors2015
Dr Alastair Greystoke
An Introduction to Stratified Medicine2015
Dr Alastair Greystoke
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD20142015
Professor Vinidh Paleri
Dr Alastair Greystoke
Dr Charles Kelly
Spindle cell carcinoma of the head and neck region: Treatment and outcomes of 15 patients2015
Dr Manolo D'Arcangelo
Dr Jane Margetts
Dr Alastair Greystoke
The use of circulating biomarkers in early clinical trials in patients with cancer2015
Dr Alastair Greystoke
A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors2014
Dr Alastair Greystoke
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer2014
Dr Alastair Greystoke
A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity2013
Dr Alastair Greystoke
Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication2013
Dr Alastair Greystoke
A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients2012
Dr Alastair Greystoke
Biomarkers of cell death applicable to early clinical trials2012
Dr Alastair Greystoke
Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer2012
Dr Alastair Greystoke
How Many Diseases Are Colorectal Cancer?2012
Dr Alastair Greystoke
Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents2012
Dr Alastair Greystoke
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer2012
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Dr Alastair Greystoke
Professor Alan Calvert
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005